

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * COOPER GLENN L MD		2. Date of Event Requiring Statement (Month/Day/Year) 09/13/2011	3. Issuer Name and Ticker or Trading Symbol CORONADO BIOSCIENCES INC [NONE]	
(Last) C/O CORONADO	(First) BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) See General Remarks	
(Street) BURLINGTON, MA 01803				5. If Amendment, Date Original Filed(Month/Day/Year)
(City)	(State)	(Zip)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Options to purchase Common Stock	(1)	10/05/2020	Common Stock	290,235	\$ 1.37	D	
Series C Convertible Preferred Stock	05/26/2011	(2)	Common Stock	30,000	\$ 5.59	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
COOPER GLENN L MD C/O CORONADO BIOSCIENCES, INC. 15 NEW ENGLAND EXECUTIVE PARK BURLINGTON, MA 01803	X		See General Remarks	

Signatures

By: /s/ Glenn L. Cooper

09/13/2011

Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) One-third of the shares will vest on each of October 5, 2011, 2012 and 2013.

Each share of Series C Convertible Preferred Stock shall be automatically converted into shares of Common Stock based on the then-effective conversion price immediately prior to the declaration or ordering of effectiveness of a resale registration filed by the issuer

(2) registering for resale by the holders thereof all of the Common Stock issuable upon conversion of the shares of Series C Convertible Preferred Stock.

Remarks:

Executive Chairman of the Board

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.